I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

CHDI 2023

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Apr 27 / Roche and Genentech
GENERATION HD2 update and further insights from the tominersen programme
GENERATION HD2 is an ongoing Phase II study of tominersen that will evaluate the safety, biomarkers and efficacy trends of tominersen in adults with prodromal and early manifest HD. This presentation outlines the study design and current status of GENERATION HD2 and provides further insights from GENERATION HD1 and GEN-EXTEND that support the design of GENERATION HD2.

Sign up or login to unlock the full suite of MEDICALLY features

Personalised Healthcare
Apr 24 / Roche and Genentech
A digital motor score for sensitive detection of disease progression in early manifest Huntington’s disease
The number of participants required for a clinical trial is directly related to how sensitively disease progression can be tracked. Huntington’s disease (HD) clinical trials often require large numbers of participants to sensitively track disease progression. This poster describes the sensitivity to change of the newly developed HD digital motor score (HDDMS), which combines selected features from the Roche HD digital monitoring platform, in people with HD-Integrated Staging System (HD-ISS) Stage 2 and Stage 3 HD, compared with the composite Unified Huntington’s Disease Rating Scale (cUHDRS).

Sign up or login to unlock the full suite of MEDICALLY features

Personalised Healthcare
Apr 24 / Roche and Genentech
A neurofilament light protein case story – test-retest reliabilities observed in GENERATION HD1, a study of tominersen in adults with manifest Huntington’s disease
Neurofilament light protein (NfL) is a fluid biomarker that correlates with Huntington’s disease (HD) pathological stage. Accurately measuring levels of NfL in the cerebrospinal fluid (CSF) may therefore provide an indication of HD progression in clinical trials. This poster describes the inter- and intra-laboratory reliability of NfL analyses conducted using the same assay at two different laboratory sites for CSF samples collected during GENERATION HD1.
04:25 PM
Duration 40mins Dubrovnik, Croatia
GENERATION HD2 update and further insights from the tominersen programme
Peter McColgan, MD, PhD

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar